AURXOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Nuo Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026

$1.26−0.04 (-3.08%)

Close on Oct 19, 2026

Market cap: $60.99M
P/E (TTM): –
Dividend yield: –

Nuo Therapeutics, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	3.31	1.37	0.61	0.11	0	0	0.15	1.37	0.72	–	12	7.76	12	11	7.25	3.91
Cost of Revenue	1.10	0.30	0.13	0.02	0	0	0.11	0.16	1.09	–	7.97	6.77	8.45	3.91	2.73	1.61
Gross Profit	2.22	1.06	0.48	0.09	0	0	0.03	1.21	-0.37	–	3.54	0.99	3.12	6.65	4.52	2.30
Research & Development	–	–	–	–	0	0	0.18	0.58	1.33	–	2.55	4.04	3.80	3.39	0.10	0.42
Selling, General & Admin	4.73	3.52	3.65	3.41	0.09	0.38	0.82	2.14	4.54	–	15	16	–	–	–	–
Selling & Marketing	–	–	–	–	0	0	0.03	0.11	0.71	–	6.24	5.78	–	–	–	–
General & Administrative	–	–	–	–	0.09	0.38	0.79	2.02	3.82	–	9.02	9.88	6.79	5.59	2.95	2.64
Operating Expenses	4.73	3.52	3.65	3.41	0.09	0.38	1.00	2.71	15	–	45	24	21	20	8.03	7.70
Operating Income	-2.52	-2.46	-3.17	-3.32	-0.09	-0.38	-0.97	-1.50	-16	–	-41	-23	-18	-13	-3.51	-5.40
Interest Expense	–	–	–	–	0	0.05	0.22	0.04	0.01	–	–	–	–	–	–	–
Interest & Investment Income	–	–	–	–	–	–	–	–	–	–	0.03	0.05	–	–	–	–
Other Non-Operating Income	0.01	0.00	0	0.00	0	0	0.00	-0.04	0.56	–	-12	4.53	-2.13	-6.89	0.02	-1.40
Merger & Restructuring Charges	–	–	–	–	–	–	–	–	–	–	–	0.70	–	–	–	–
Asset Impairment Charges	0	0	0	–	–	–	–	–	9.30	0	0	4.68	–	–	–	–
Gain (Loss) on Sale of Assets	–	–	–	–	0	0	-0.02	-0.01	0.00	–	-0.01	-0.13	0	-0.08	0.04	-0.01
Pretax Income	-2.51	-2.32	-3.17	-3.17	-0.09	-0.09	-1.19	-1.54	-15	–	-53	-19	-20	-20	-3.49	-6.80
Income Tax Expense	0	0	0	0	0	0	0	–	–	–	-0.09	0.02	0.02	0.02	0.02	0.01
Net Income	-2.51	-2.32	-3.17	-3.17	-0.09	-0.09	-1.19	-1.54	-15	–	-53	-19	-20	-20	-3.51	-6.82
Net Income to Common	–	–	–	-3.17	-0.89	7.71	-1.19	-1.54	-15	–	–	-19	-20	-20	-3.86	-9.04
EPS (Basic)(per share)	-0.05	-0.05	-0.08	-0.08	-0.03	0.30	-0.05	-0.07	-1.02	–	-0.42	-0.16	-0.20	-0.24	-0.08	-0.23
EPS (Diluted)(per share)	–	–	–	–	-0.03	0.27	-0.05	-0.07	-1.02	–	-0.42	-0.16	-0.20	-0.24	-0.08	-0.23
Shares Outstanding (Basic, Weighted)(shares)	47	45	42	40	30	26	24	23	15	–	126	121	104	82	51	–
Shares Outstanding (Diluted, Weighted)(shares)	47	45	42	40	30	27	24	23	15	–	126	121	104	82	51	–
EBITDA	–	–	–	–	-0.09	-0.38	-0.88	-1.40	-14	–	-41	-23	-17	-12	-2.88	-4.96

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 64.1%
Operating margin: -33.3%
Net margin: -38.7%
Return on equity, FY2025: 1134.6%

Financial strength

Current ratio: 1.28
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 28.9%

Valuation

P/E ratio: –
Price to sales: 11.73
Price to book: –
Dividend yield: –